II. Indications

  1. Hepatitis B risk for fibrosis
  2. Metabolic Liver Disease assessment for Fibrosis (MASH, NASH)

III. Contraindications

  1. Not validated in age <35 years (consider elastography instead in this, younger population)

IV. Criteria

  1. Score = (Age x AST) / (PlateletCount x sqrRoot(ALT))

V. Interpretation: MASLD (Metabolic Liver Disease)

  1. Score <1.30 (<1.9-2 in age >65 years)
    1. Low risk for advanced Hepatic Fibrosis
    2. Negative Predictive Value: 95%
  2. Score 1.3 to 2.67 (or 2 to 2.67 in age >65 years)
    1. Intermediate risk for advanced Hepatic Fibrosis
    2. Requires secondary assessment methods (e.g. elastography, Ultrasound)
  3. Score >2.67
    1. High risk for advanced hepatitc fibrosis

VI. Interpretation: Hepatitis C

  1. Score <1.45
    1. Negative Predictive Value (NPV) in Hepatitis CVirus related fibrosis: 80%
  2. Score >3.25 (>2.67 in NAFLD)
    1. Positive Predictive Value for Hepatic Fibrosis >80%

VII. Efficacy

Images: Related links to external sites (from Bing)